Member Info for Teamhanz

Hi Riddler -

June 2021 Q&A -

Regarding the collaboration with Physiomics, have they completed all the necessary work for VAL201?
Can you share with us the order in which Physiomics will conduct modelling on our drugs? We have
given them three drugs, VAL201, VAL301 and BC201, Which is first, second and third?
Have you explored with PYC the potential for use in sepsis using VALl201?

The Company announced the extension of the agreement with Physiomics plc (AIM: PYC) in January
2021. This detailed that Physiomics will be carrying out a programme of work spread over a 9-month
period to consider all three programmes that use the VAL201 peptide as an active ingredient – VAL201 in
prostate cancer, VAL301 in endometriosis and BC201, the collaborative project with Black Cat Bio and
OncoLytika considering the peptide in the treatment of patients with severe symptoms of Covid-19.
The programme of works provides an analysis of the clinical data collected for VAL201, and the
comparison of this to the preclinical data generated for all three programmes, aiming to provide
additional scientific evidence of the mechanisms of action and proposing hypotheses to be tested in
further clinical or preclinical testing on all of these projects.
As the behaviour of the peptide in the cell will have similar characteristics regardless of the disease
studied, the work is not split strictly into the project areas – i.e. it is not the case that they will work on
the projects sequentially. The behaviour of the peptide will be modelled based on the data generated,
and conclusions relating to each project can then be drawn from those models.
At the current time, Physiomics have carried out analysis on the clinical data, and when the new
preclinical data being generated for the endometriosis project (detailed above) and for BC201 (detailed
below) are available, they will continue to amalgamate these new data points into their models.
The conclusions surrounding BC201 will be applied to the understanding of whether the peptide could
also be used as a treatment of sepsis. The increased overall understanding of the activity of the peptide,
by Physiomics and by our Scientific Advisory Board will enable better understanding of all potential
applications of the peptide.

Yes, Suzy stated in a Q&A Riddler that the 'clinical work' had been completed and that the preclinical work (301 and Bc201) would be incorporated when they had further news/results come through. So fingers crossed, a deal could be anytime now.

Hi Porky, where did you get the ‘transformative year’ quote from? Many thanks.

Literally not heard a thing for ages except for a Poll on how to communicate better haha

If a deal comes through with an upfront payment there will be no reason to dilute what so ever!

No, which is why I find that strange. Nothing price sensitive and why would you not be shouting it from the roof tops if, like you say the desired outcomes have been achieved. Unless the radio silence is due to the fact that the deal is being completed as we speak, hence no Q&A as an announcement is very near? Who knows.

awww yes but she also clearly stated that the 'clinical' work has been completed. 201, free to share completed pyc work. 301 and bc201 will continue to be analysed until the end of that work. 201 is ready to be partnered.

Where's this zoom call next week come from?

1 trade through. Hold on to your hats!

Yeah, actually with you on that one TDK.

Not unless there is any news.

In a recent Q&A the Valirx CEO stated that PYC had completed the work for the clinical part of the work and as results and info for the pre clinical drugs come through PYC will be working on those. The work has to be finished by mid November but with the clinical side of thing finished, a deal could be announced before. Just, how long is a piece of string is the problem.

Still no news flow or Q&A... They are taking full advantage now of not having IAR on their case haha. I miss that dude. He was a funny chap. Actually missing A1 too its that barren here!

No, he doesn't. That was his last sentence!

Well put PM22. I think she may have made a rod for her own back releasing a note saying 'Block buster year'. Still time, yes, but we haven't had an update on any of the drugs and their current standings, 301 is just pushed that pretty much however long the Japanese want to test, no probs, 201 talking to the big boys and girls, 401s funding is how long is a piece of string and now Bc201 is pretty much in that same category and nothing about any companies with regards to their new strategy....And now no Q&A as it's the same questions?

*Progress report*

Progress on all the drugs would be good!

hahaha back to the grind stone.

Morning RB. how was your holiday?

Thanks Andysel. I have been in Valirx for 8 years, so know the company inside and out (Hence not knowing how deals are completed) hahaha